Stacey A. Cohen, MD

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd

ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD

July 19th 2023

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib

ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD

July 19th 2023

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

Assessing HER2 Expression in Metastatic Colorectal Cancer

ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD

July 12th 2023

Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.

Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer

ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD

July 12th 2023

Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.

Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy

ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD

July 5th 2023

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study

ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD

July 5th 2023

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.

Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer

ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD

June 28th 2023

Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.

Colorectal Cancer: Evolving Role of ctDNA Testing in Practice

ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD

June 28th 2023

A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.

ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer

ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD

June 21st 2023

A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.

Biomarker Testing in Metastatic Colorectal Cancer

ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD

June 21st 2023

Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.

Dr. Cohen on the Timing of ctDNA Testing in Resected Stage I-III CRC

ByStacey A. Cohen, MD

January 31st 2023

Stacey A. Cohen, MD, discusses the investigation of the optimal timing to test for circulating tumor DNA to detect minimal residual disease following surgery in patients with stage I to III colorectal cancer.

Dr. Cohen on the Use of ctDNA for Chemotherapy Decisions in CRC

ByStacey A. Cohen, MD

October 26th 2022

Stacey A. Cohen, MD, discusses the evaluation of the role of circulating tumor DNA to determine the benefit of chemotherapy in colorectal cancer.

Stacey A. Cohen, MD, of Seattle Cancer Care Alliance

Dr. Cohen on the Shortcomings of Trials Evaluating Cytoreductive Surgery and HIPEC in CRC

ByStacey A. Cohen, MD

September 24th 2021

Stacey A. Cohen, MD, discusses the shortcomings of clinical trials evaluating cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Dr. Cohen on the Importance of Patient Selection for HIPEC Surgery in CRC

ByStacey A. Cohen, MD

September 9th 2021

Stacey A. Cohen, MD, discusses the importance of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.